Other formats:
BibTeX
LaTeX
RIS
@article{1623023,
author = {Hajek, Roman and Delforge, Michel and Raab, Marc S. and Schoen, Paul and DeCosta, Lucy and Spicka, Ivan and Radocha, Jakub and Pour, Luděk and GonzalezandMcQuire, Sebastian and Bouwmeester, Walter},
article_location = {Hoboken},
article_number = {4},
doi = {http://dx.doi.org/10.1111/bjh.16105},
keywords = {algorithm; multiple myeloma; overall survival; relapsed; risk stratification},
language = {eng},
issn = {0007-1048},
journal = {British journal of haematology},
title = {Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma},
url = {http://dx.doi.org/10.1111/bjh.16105},
volume = {187},
year = {2019}
}
TY - JOUR
ID - 1623023
AU - Hajek, Roman - Delforge, Michel - Raab, Marc S. - Schoen, Paul - DeCosta, Lucy - Spicka, Ivan - Radocha, Jakub - Pour, Luděk - Gonzalez-McQuire, Sebastian - Bouwmeester, Walter
PY - 2019
TI - Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma
JF - British journal of haematology
VL - 187
IS - 4
SP - 447-458
EP - 447-458
PB - Wiley-Blackwell
SN - 00071048
KW - algorithm
KW - multiple myeloma
KW - overall survival
KW - relapsed
KW - risk stratification
UR - http://dx.doi.org/10.1111/bjh.16105
L2 - http://dx.doi.org/10.1111/bjh.16105
N2 - Multiple myeloma (MM) is a malignancy with varying survival outcomes and drivers of disease progression. Existing MM staging tools were developed using data from newly diagnosed patients. As patient characteristics and disease-related factors change between diagnosis and the initiation of second-line (2L) treatment, an unmet need exists for a tool that can evaluate risk of death at first relapse. We have developed a risk stratification algorithm (RSA) using data from patients with MM who were at 2L. Hazard ratios for independent predictors of overall survival (OS) were derived from a Cox models, and individual patient scores were calculated for total risk. K-adaptive partitioning for survival was used to stratify patients into groups based on their scores. Relative risk doubled with ascending risk group; median OSs for patients in group 1 (lowest risk)-4 (highest risk) were 61 center dot 6, 29 center dot 6, 14 center dot 2 and 5 center dot 9 months, respectively. Differences in OS between risk groups were significant. Similar stratification was observed when the RSA was applied to an external validation data set. In conclusion, we have developed a validated RSA that can quantify total risk, frailty risk and disease aggressiveness risk, and stratify patients with MM at 2L into groups with profoundly different survival expectations.
ER -
HAJEK, Roman, Michel DELFORGE, Marc S. RAAB, Paul SCHOEN, Lucy DECOSTA, Ivan SPICKA, Jakub RADOCHA, Luděk POUR, Sebastian GONZALEZ-MCQUIRE and Walter BOUWMEESTER. Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma. \textit{British journal of haematology}. Hoboken: Wiley-Blackwell, 2019, vol.~187, No~4, p.~447-458. ISSN~0007-1048. Available from: https://dx.doi.org/10.1111/bjh.16105.
|
